SEC Tracker
Get the app
IDXG · XBRL financial data

Interpace Biosciences financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal years (IDXG's year ends in late December)

In thousands of dollarsDec 31, 2020Dec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025
Revenue—8,1975,678———
Revenue from contracts with customers32,39841,31431,83840,21446,92638,728
Cost of revenue21,67323,36913,60716,31017,00114,598
Gross profit10,72517,94518,23123,90429,92524,130
Research and development2,7951,882703636676642
General and administrative20,77013,66910,9739,3639,4869,480
Total operating expenses36,79131,94221,84821,10021,81720,046
Other operating income (expense)————(499)(142)
Operating income (loss)(26,066)(13,997)(3,617)2,8048,1084,084
Interest expense549—————
Other income (expense)467(496)(1,211)(667)——
Income tax expense (benefit)53(667)29174(21,210)
Net income (loss)(26,451)(14,943)(21,958)8026,70224,575
Earnings per share, basic USD per share—(3.61)(5.18)0.191.425.55
Earnings per share, diluted USD per share——(5.18)0.180.400.89
Weighted average shares, basic thousands of shares4,0294,1354,2384,3174,3874,424
Weighted average shares, diluted thousands of shares4,0294,1354,2384,36415,73427,695

Balance sheet

CSV

Fiscal years (IDXG's year ends in late December)

In thousands of dollarsDec 31, 2020Dec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025
Cash and cash equivalents2,7723,0644,8283,4981,4612,505
Accounts receivable8,0286,1585,0324,9838,5445,649
Inventory2,0521,7861,2241,2271,2111,114
Total current assets14,12212,16612,15410,32211,7739,900
Property and equipment, net7,3496,3494807901,3611,423
Right-of-use asset4,3844,0322,4391,8641,6131,217
Goodwill8,4338,433————
Total assets45,68138,42715,97913,02114,79233,838
Accounts payable4,5112,6941,0501,5441,659983
Total current liabilities18,23315,68214,28317,47410,6155,103
Lease liability, non-current3,5403,1541,8481,4721,183752
Total liabilities28,22834,30932,51528,15717,00911,475
Accumulated deficit(212,116)(227,059)(249,017)(248,215)(235,380)(210,805)
Total stockholders' equity(29,083)(42,418)(63,072)(61,672)(2,217)22,363
Total liabilities and equity45,68138,42715,97913,02114,79233,838
Common shares outstanding (cover page) thousands of shares4,1124,2264,3114,3764,42327,701

Cash flows

CSV

Fiscal years (IDXG's year ends in late December)

In thousands of dollarsDec 31, 2020Dec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025
Net income (loss)(26,451)(14,943)(21,958)8026,70224,575
Stock-based compensation2,1871,2551,25863029135
Depreciation and amortization5,5015,3742,5601,026300425
Net cash from operating activities(13,979)(8,719)(7,692)3,7894,6465,831
Purchases of property and equipment1,575354322470876356
Net cash from investing activities(1,575)(315)6,206(87)(876)(356)
Proceeds from issuing common stock434335108———
Net cash from financing activities16,6058,9763,000(5,032)(5,807)(4,431)
Net change in cash1,051(58)1,514(1,330)(2,037)1,044

Compare with peers

SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
Interpace Biosciences2,6889,13198*27.7M— 10-QJun 30, 2026
Global Innovative Platforms24451(134)*49.8M1.8 quarters 10-QJun 30, 2026
ENDRA Life Sciences1,740not reported(928)*1.5M1.9 quarters 10-QJun 30, 2026
Bluejay Diagnostics9,599not reported(1,499)*4.5M6.4 quarters 10-QJun 30, 2026
Stimcell Energetics6.9not reported(109)21.1M0.1 quarters 10-QAug 31, 2026
LogicMark3,4963,34983*899,759— 10-QJun 30, 2026
INVO Fertility3,7332,175(1,101)*2.5M3.4 quarters 10-QJun 30, 2026
Semler Scientific10,1767,491(32,950)*15.2M0.3 quarters 10-QSep 30, 2025
Nu-Med Plus5.401.1*83.5M— 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.